A new genetic test could determine whether standard treatments like chemotherapy will work for breast cancer patients.
Researchers looked at about three hundred patients with stage two or stage three breast cancer. They determined how patients responded to various cancer treatments.
Those results were compared to the patients' genetic markers, which can predict a positive or negative response to chemo. Doctors used that data to identify patients who were more likely to survive after getting chemotherapy.
Their research could lead to more personalized and more effective treatments. The study is published in the Journal of the American Medical Association.